The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,411,107 in first-year total cost, median $2,205,554.
Most frequent study sections
- Special Emphasis Panel[ZTR1 NTU-3 (01)]1
- Special Emphasis Panel[ZTR1 NTU-3 (03)]1
Most frequent institutions
- SOUND PHARMACEUTICALS, INC.1
- UNIVERSITY OF PENNSYLVANIA1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation studies to Evaluate the Safety and Efficacy of SPI-1005 in Moderate and Severe COVID-19 Patients1U01TR003853-01 | KIL, JONATHAN | SOUND PHARMACEUTICALS, INC., WA | $3,082,804 | ZTR1 |
| 2021 | Efficacy of Fenofibrate for COVID-19: A phase II randomized controlled trial1U01TR003734-01 | CHIRINOS MEDINA, JULIO ALONSO | UNIVERSITY OF PENNSYLVANIA, PA | $1,328,303 | ZTR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.